Project Grant R21NS136065
Award Date
9/19/24
Completion Date
8/31/26
Dollars Obligated
$444K
Federal Agency
National Institute of Neurological Disorders and Stroke
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
This $2,569,851 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), supports research to investigate how the PD-L1/PD-1 immune checkpoint pathway controls physiological and pathological pain, as well as opioid analgesia, through neuronal, immune, and glial mechanisms. The project aims to validate the actions of PD-L1 and the checkpoint inhibitor nivolumab on neuroinflammation and...
The Project Grant award R61NS133704, totaling $1,846,202.00, was provided by the National Institute of Neurological Disorders and Stroke under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Duke University. The primary objective is to develop potent, selective, and peripherally-restricted antagonists of the adrenergic receptor beta-3 (ADRB3) for the treatment of chronic primary pain conditions affecting over 100 million people. This will involve: 1) developing novel ADRB3...
This $2,249,392 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to validate senescent cells as a target for the treatment of chronic pain in aging. The project aims to rigorously characterize the role of senescent neurons and their senescence-associated secretory phenotype (SASP) in driving dorsal root ganglion hyperexcitability and persistent pain following...
This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
The National Institute on Drug Abuse (NIDA) awarded a $154,568 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Washington University in St. Louis. The grant, titled "Investigating the Role of Dorsal Raphe Nucleus Enkephalin Neurons in Motivational and Affective Behaviors During Chronic Pain", aims to determine the contribution of endogenous opioids in the dorsal raphe nucleus to motivational and affective dysregulation during chronic pain. The...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
This $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of Schwann cell PIEZO1 in pain sensation. The key objectives are to: 1) develop and validate adeno-associated virus (AAV) vectors for selective inhibition of Schwann cell PIEZO1, and 2) determine the sensory effects of Schwann cell...
This federal Project Grant award of $517,494.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research at Duquesne University to investigate sex-specific differences in gene expression and RNA splicing patterns in the dorsal root ganglia during pain and pain relief. The key objectives are to define the differentially expressed RNA splice isoforms of the...
This $5,037,022 project grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke will support the development of novel single-cell technologies called "Raman2omics" to map pain-associated genes and cells across the lifespan. Funded under the Drug Abuse and Addiction Research Programs, the grant to the Massachusetts General Hospital aims to apply Raman2omics to systematically investigate genes and cells associated with postoperative pain...
This Project Grant award of $2,068,842 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to identify how pain influences the activity of prefrontal cortical dynorphin neurons and their role in modulating nociception and maladaptive affective behaviors. The research aims to dissect the mechanisms by which dynorphin neurons and release of dynorphin neuropeptides or fast neurotransmitters...